Compound: testosterone enanthate
SMILES: O=C1C=C2[C@]([C@@H]3[C@H]([C@H]4[C@]([C@@H](OC(=O)CCCCCC)CC4)(C)CC3)CC2)(C)CC1
InChIKey: VOCBWIIFXDYGNZ-IXKNJLPQSA-N
Synonyms: testosterone enanthate, 315-37-7, Androtardyl, Testosterone heptanoate, Testinon, Testosterone enantate, Everone, Testosterone heptylate, Testosterone 17-enanthate, NSC-17591, Testate, Xyosted, 17-Hydroxyandrost-4-en-3-one, 17-heptanoate, 17-((1-Oxoheptyl)oxy)androst-4-en-3-one, Testosterone enanthate ciii, Testosteroni enantas, 7Z6522T8N9, 3-oxoandrost-4-en-17beta-yl heptanoate, Androst-4-en-3-one, 17-(1-oxoheptyl)oxy-, (17beta)-, CHEBI:9464, 17-heptanoyl-17beta-hydroxyandrost-4-en-3-one, DTXSID701016540, NSC17591, 17-[(1-Oxoheptyl)oxy]androst-4-en-3-one, Primosteston, Testo-Enant, Andro LA, Xyosted (Autoinjector), RefChem:56107, DTXCID901474730, 206-253-5, Delatestryl, Atlatest, Testanthate, Testoenant, Orquisteron-E, Exten test, Depo-Testro Med, Andropository, Durathate, Testenate, Testosterone heptoate, Reposo TMD, Reposo-TMD, Malogen L.A., DePatestrye, Malogen L.A.200, Testonenant, Ditate, Andro L.A. 200, Delatest, Testosterone, heptanoate, Heptanoic acid, ester with testosterone, 17beta-Enanthoxyandrost-4-en-3-one, 4-Androsten-3-one 17beta-enanthate, Androgyn L.A., Androst-4-en-3-one, 17-[(1-oxoheptyl)oxy]-, (17b)-, 17beta-Hydroxyandrost-4-en-3-one enanthate, Androst-4-en-3-one, 17-((1-oxoheptyl)oxy)-, (17beta)-, Testosterone 17-heptanoate, [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate, (8R,9S,10R,13S,14S,17S)-10,13-Dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl heptanoate, Testosterone ethanate, CCRIS 7082, EINECS 206-253-5, BRN 3170544, Androst-4-en-3-one, 17-[(1-oxoheptyl)oxy]-, (17.beta.)-, UNII-7Z6522T8N9, Testosterone enanthate [USP:JAN], Delatestryl (TN), Androst-4-en-3-one, 17beta-hydroxy-, heptanoate, Ditate (Salt/Mix), Deladumone (Salt/Mix), Testosterone heptoic acid, Testosterone enantate CRS, SCHEMBL42687, Androgyn L.A. (Salt/Mix), 4-08-00-00979 (Beilstein Handbook Reference), Testosterone 17beta-heptanoate, CHEMBL1200335, Androst-4-en-3-one, heptanoate, Testosterone 17beta-heptanoic acid, TESTOSTERONE ENANTHATE [MI], Testosterone enanthate (JP18/USP), TESTOSTERONE ENANTHATE [JAN], LMST02020075, MFCD00055890, s3717, Androst-4-en-3-one,(17.beta.)-, TESTOSTERONE ENANTATE [MART.], TESTOSTERONE ENANTHATE [VANDF], AKOS015960945, TESTOSTERONE ENANTATE [WHO-IP], CCG-268655, DB13944, TESTOSTERONE ENANTHATE [USP-RS], TESTOSTERONE ENANTHATE [WHO-DD], 4-Androsten-3-one 17.beta.-enanthate, AC-12599, DS-11585, FT158490, Testosterone enanthate, analytical standard, 4-Androsten-17beta-ol-3-one 17-enanthate, TESTOSTERONE ENANTATE [EP MONOGRAPH], TESTOSTERONE ENANTHATE [ORANGE BOOK], TESTOSTERONI ENANTAS [WHO-IP LATIN], 17beta-hydroxyandrost-4-en-3-one heptanoate, NS00015428, TESTOSTERONE ENANTHATE CIII [USP-RS], TESTOSTERONE ENANTHATE [USP MONOGRAPH], WLN: L E5 B666 OV MUTJ A E FOV6, C08157, D00958, DITATE-DS COMPONENT TESTOSTERONE ENANTHATE, Testosterone enantate for peak identification CRS, Testosterone enantate for system suitability CRS, 17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid, SR-01000942262, SR-01000942262-1, Androst-4-en-3-one, 17.beta.-hydroxy-, heptanoate, BRD-K89657519-001-01-8, Q27108402, 3-Oxoandrost-4-en-17-yl heptanoate, (17.beta.)- #, 17.BETA.-(HEPTANOYLOXY)ANDROST-4-EN-3-ONE [WHO-IP], 17- [(1- Oxoheptyl) oxy] - (17?) -androst- 4- en- 3- one, ANDROST-4-EN-3-ONE, 17-(1-OXOHEPTYL)OXY-, (17.BETA.)-, Testosterone enantate, European Pharmacopoeia (EP) Reference Standard, Testosterone enanthate, United States Pharmacopeia (USP) Reference Standard, Testosterone enantate for peak identification, European Pharmacopoeia (EP) Reference Standard, Testosterone enantate for system suitability, European Pharmacopoeia (EP) Reference Standard
Theoretical properties:
molecular_formula: C26H40O3
molecular_weight: 400.6 g/mol
exact_mass: 400.29774513 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 7
heavy_atom_count: 29
topological_polar_surface_area: 43.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 34-39ºC
solubility: Insoluble
Descriptions:
pubchem: Testosterone Enanthate can cause developmental toxicity according to state or federal government labeling requirements.
chembl: TESTOSTERONE ENANTHATE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Testosterone enanthate is used in the treatment of low testosterone levels in men. It is also used in hormone therapy for women and transgender men. It is given by injection into muscle or subcutaneously usually once every one to four weeks.
Side effects of testosterone enanthate include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire. The drug is a synthetic androgen and anabolic steroid and hence is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT).  Testosterone enanthate is a testosterone ester and a long-lasting prodrug of testosterone in the body. Because of this, it is considered to be a natural and bioidentical form of testosterone, which makes it useful for producing masculinization and suitable for androgen replacement therapy. Esterase enzymes break the ester bond in testosterone enanthate, releasing free testosterone and enanthic acid through hydrolysis.

 This process ensures a sustained release of testosterone in the body.
Testosterone enanthate was introduced for medical use in 1954. Along with testosterone cypionate, testosterone undecanoate, and testosterone propionate, it is one of the most widely used testosterone esters. In addition to its medical use, testosterone enanthate is used to improve physique and performance. The drug is a controlled substance in many countries and so non-medical use is generally illicit.